Causaly
Cross-listing: Causaly already exists in Scientific / research AI memory. This row adds the use-case agent harness framing: London-based biomedical-research AI for drug-discovery teams. $60M Series B 2023 (Index + ICONIQ). 25M+ scientific articles indexed; causal-graph-grounded.
Active · Verified 2026-10-28 · fresh as of 2026-10-28 · 19 cited facts, 0 with a third-party source · 1 recorded change · Suggest a correction
At a glance
- Type
- Biomedical knowledge-graph + AI research agent vendor fix
- Tier
- T2
- Created
- 2017 (founded) vendor fix
- Latest release
- not applicable — wrong section fix
- License
- not applicable — not OSS fix
- GitHub
- not applicable — no GitHub repo fix
- Pricing
- not applicable — wrong section fix
- Funding
- $93M total raised (per Causaly about page) vendor fix
- Freshness
- 2026-10-28 fix
- Layer
- agent-infra repo fix
- Licensing
- commercial vendor fix
- Protocols
- a2a, mcp-server vendor fix
When to use
Optimised for: drug-discovery + biomedical research + causal-graph search
Anti-fit: not applicable — wrong section
Pros & cons
Pros
Causal-graph differentiator vs vanilla RAG-on-PubMed; Pfizer-grade customer base; Index + ICONIQ.
Cons
Biomedical-only ICP; expensive enterprise pricing; smaller than AlphaSense.
Claims & capabilities
$60M Series B 2023 (Index + ICONIQ; reportedly $300M+ val); 25M+ articles; causal-graph search
Technical surface
- API surface
- not applicable — wrong section
- Backend storage
- not applicable — wrong section
- Deployment
- not applicable — wrong section
- Embedding model
- not applicable — not a memory product
- Multi-tenancy
- not applicable — wrong section
- MCP
- yes — Causaly scientific capabilities (literature, knowledge graph, workflows) callable via MCP, A2A and APIs
- A2A
- not applicable — wrong section
- OpenTelemetry
- not applicable — wrong section
Alternatives to Causaly → live options ranked by shared design, licence, hosting and MCP support
Similar systems
Other use-case-specific agent harnesses in the catalog, ranked by inbound references.
- Calypso AI (now F5 AI Guardrails) T2
Dublin / NYC founded 2018; GenAI security and content scanning. $23M Series A-1 Aug-2024 (Paladin Capital + Lockheed Martin Ventures). Pivoted from defence ML to enterprise GenAI guardrails 2023-24.
- Salesforce Agentforce T1
Cross-listing: Salesforce Agentforce already exists under Vertical / Customer-support / voice memory; this row is the Agent-harness framing — Agentforce as the consumer-facing agent IDE / builder on Data Cloud. Agentforce launched Sep-2024; Agentforce 2.0 announced Dec-2024.
- Lasso Security T2
Tel-Aviv-founded LLM security platform — adversarial testing, prompt-injection defence, data-leakage prevention. $6M seed Nov-2023 (Entrée Capital + Samsung Next).
- Pillar Security T2
Tel-Aviv-founded (Dor Sarig + Ziv Karliner, both ex-IDF cyber); end-to-end LLM security platform — discovery, red-teaming, runtime guardrails. $9M seed Apr-2024 (Shield Capital + Greenfield).
- Promptfoo T2
OSS (MIT) prompt-engineering eval and red-team CLI; supports OWASP LLM Top-10 vulnerability tests, jailbreak generation, and CI/CD pipeline integration. $5M seed Mar-2024 (Andreessen Horowitz). Founders ex-Discord + ex-Smile Identity.
- Protect AI T2
Founded 2022 by Ian Swanson + Daryan Dehghanpisheh (ex-AWS); AI/ML supply-chain + GenAI security. Acquired by Palo Alto Networks (2025-07-22; announced Apr-2025, reported $700M); its capabilities now ship in Prisma AIRS. Products: Recon (red-team), ModelScan (model artifact scanner), Sightline (vulnerability DB).
Sources (18 cited facts, 0 third-party)
Each fact links to the page it came from; the badge says who published it (how to read sources).
- What it is Biomedical knowledge-graph + AI research agent vendor
- What it does & what's distinct Cross-listing: Causaly already exists in Scientific / research AI memory. This row adds … vendor
- Claims / benefits $60M Series B 2023 (Index + ICONIQ; reportedly $300M+ val); 25M+ articles; causal-graph … vendor
- Created 2017 (founded) vendor
- Funding $93M total raised (per Causaly about page) vendor
- Customers / scale Pfizer, AstraZeneca, Bristol Myers Squibb, GSK vendor
- HQ London vendor
- Founders / pedigree Yiannis Kiachopoulos (CEO); Artur Saudabayev (CTO) vendor
- MCP support yes — Causaly scientific capabilities (literature, knowledge graph, workflows) callable … vendor
- Optimised for drug-discovery + biomedical research + causal-graph search vendor
- Pros Causal-graph differentiator vs vanilla RAG-on-PubMed; Pfizer-grade customer base; Index … vendor
- Cons Biomedical-only ICP; expensive enterprise pricing; smaller than AlphaSense. vendor
- Project & sources www.causaly.com/ vendor
- architecture-deployment-locus cloud vendor
- licensing-bucket commercial vendor
- positioning-platform-vs-product product vendor
- taxonomy-three-layer-rollup agent-infra repo
- protocol-support a2a,mcp-server vendor
What changed
Changes to this record's lifecycle, licence, release, pricing and hosting facts, from the catalog's git history. Subscribe (Atom)